Processa Pharmaceuticals, Inc. (PCSA)
PCSANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.87
-0.0800 (-4.10%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $5.23m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.04 to $8.88
- Average volume
- 92.5k
- Previous close
- $1.95
Earnings
Next report Nov 12, 2026
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.49m | -$3.70m | -$3.33m | -$2.34m |
| Net income | -$3.44m | -$3.36m | -$3.38m | -$3.27m |
News
8 latest- Processa Pharmaceuticals, Inc. Outlines Strategic Direction and Expected Capitalization of 309.3 million As-Converted SharesFintel · 5 days ago
- Processa Pharmaceuticals, Inc. Appoints Gregory J. Flesher as Chief Operating Officer and Announces Key Leadership AdditionsFintel · 6 days ago
- Processa Pharmaceuticals, Inc. Appoints Dr. Sheila Gujrathi as Executive Chair and Announces FDA Clearance of Phase 2 IND for VT-7208Fintel · Oct 29, 2026
- Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals RTTNews · Jul 31, 2026
- Processa Pharmaceuticals Acquires Vidya Therapeutics, Launch $200M Financing; Stock Down RTTNews · Jul 29, 2026
- Processa Pharmaceuticals To Acquire Vidya Therapeutics, Launch $200M Financing; Stock Down RTTNews · Jul 29, 2026
- Top Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch... RTTNews · Jun 11, 2026
- Processa Pharmaceuticals (PCSA) Price Target Increased by 2,400.00% to 25.50Fintel · Dec 21, 2025
The company
Processa Pharmaceuticals is a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory (I&I) diseases through a disciplined, science-driven development strategy. Following the acquisition of Vidya Therapeutics, Processa's lead program is VT-7208, a potentially best-in-class oral Bruton's tyrosine kinase inhibitor (BTKi) therapy designed to improve on efficacy and safety of earlier-generation BTKi programs. Processa is developing VT-7208 in food allergy, chronic spontaneous urticaria (CSU), relapsing multiple sclerosis (RMS) and exploring additional immune-mediated diseases. Processa's second program is a potentially best-in-class, preclinical oral neonatal Fc receptor (FcRn) antagonist being explored for treatment of immune-mediated diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- processapharmaceuticals.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.